Acrivon Therapeutics (ACRV) Institutional Ownership $2.15 +0.65 (+43.33%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$2.13 -0.02 (-0.98%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Acrivon Therapeutics (NASDAQ:ACRV)CurrentInstitutional OwnershipPercentage71.62%Number ofInstitutional Buyers(last 12 months)22TotalInstitutional Inflows(last 12 months)$23.68MNumber ofInstitutional Sellers(last 12 months)11TotalInstitutional Outflows(last 12 months)$2.32M Get ACRV Insider Trade Alerts Want to know when executives and insiders are buying or selling Acrivon Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ACRV Institutional Buying and Selling by Quarter Remove Ads Acrivon Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails3/12/2025Wealthedge Investment Advisors LLC10,857$65K0.0%N/A0.035% 2/17/2025Nuveen Asset Management LLC13,402$81K0.0%-48.0%0.043% 2/17/2025OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 102,784$619K0.0%+29.7%0.330% 2/17/2025Corton Capital Inc.12,159$73K0.0%N/A0.039% 2/17/2025Bridgeway Capital Management LLC74,600$449K0.0%-3.1%0.240% 2/17/2025Citadel Advisors LLC2,119,646$12.76M0.0%-1.0%6.807% 2/17/2025Acorn Capital Advisors LLC405,237$2.44M1.3%N/A1.301% 2/14/2025Northern Trust Corp117,323$706K0.0%+11.3%0.377% 2/14/2025Dimensional Fund Advisors LP37,063$223K0.0%+20.2%0.119% 2/13/2025Marshall Wace LLP597,794$3.60M0.0%-26.2%1.920% Get the Latest News and Ratings for ACRV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/13/2025Barclays PLC38,091$228K0.0%+14.4%0.122% 2/13/2025Renaissance Technologies LLC49,400$297K0.0%+7.6%0.159% 2/12/2025Trexquant Investment LP16,871$102K0.0%-44.5%0.054% 2/12/2025JPMorgan Chase & Co.25,809$155K0.0%-24.1%0.083% 2/11/2025American Century Companies Inc.17,588$106K0.0%+14.2%0.056% 2/6/2025Charles Schwab Investment Management Inc.113,840$685K0.0%-2.1%0.366% 2/4/2025Bank of New York Mellon Corp27,635$166K0.0%-6.4%0.089% 1/24/2025China Universal Asset Management Co. Ltd.6,602$40K0.0%N/A0.021% 12/26/2024JPMorgan Chase & Co.33,991$238K0.0%+548.3%0.109% 12/13/2024Exome Asset Management LLC116,757$817K0.5%N/A0.375% 11/19/2024Barclays PLC33,306$233K0.0%+51.2%0.107% 11/16/2024Geode Capital Management LLC302,103$2.12M0.0%-2.0%0.975% 11/15/2024Barclays PLC33,306$233K0.0%+51.2%0.108% 11/15/2024State Street Corp225,896$1.58M0.0%+26.4%0.729% 11/12/2024Charles Schwab Investment Management Inc.116,253$814K0.0%-19.2%0.375% 10/10/2024Exchange Traded Concepts LLC20,348$142K0.0%-52.5%0.066% 8/16/2024Perceptive Advisors LLC5,360,858$31.09M0.7%+78.2%17.362% 8/14/2024Marshall Wace LLP948,866$5.50M0.0%+58.8%3.073% 8/13/2024Sands Capital Ventures LLC2,122,605$12.31M4.1%+28.4%6.874% 8/12/2024XTX Topco Ltd10,493$61K0.0%N/A0.034% 8/9/2024Renaissance Technologies LLC54,500$316K0.0%-46.9%0.177% 8/9/2024Dimensional Fund Advisors LP10,066$58K0.0%N/A0.033% 8/1/2024 Rhumbline Advisers16,209$94K0.0%+48.9%0.052% 7/26/2024Bank of New York Mellon Corp36,632$212K0.0%+50.1%0.119% 5/15/2024Baker BROS. Advisors LP52,885$378K0.0%N/A0.234% 5/14/2024American International Group Inc.6,016$43K0.0%+39.2%0.027% 5/10/2024Vanguard Group Inc.507,185$3.63M0.0%+6.6%2.241% 1/5/2024Exchange Traded Concepts LLC13,289$65K0.0%+34.0%0.060% 11/13/2023Federated Hermes Inc.226,375$2.16M0.0%-25.6%1.020% 9/21/2023Barclays PLC14,263$184K0.0%-16.0%0.065% The Crypto Market is About to Change Lives (Ad)I've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free. Claim your FREE copy of my controversial book before I change my mind.8/10/2023AAF Wealth Management LLC10,678$138K0.1%N/A0.049% 7/20/2023Exchange Traded Concepts LLC11,709$152K0.0%N/A0.053% 5/8/2023Federated Hermes Inc.613,625$7.79M0.0%-25.5%2.798% 2/16/2023HealthCor Management L.P.284,201$3.27M3.0%N/A1.360% 2/14/2023RA Capital Management L.P.4,810,508$55.42M1.1%N/A23.028% 2/13/2023Sands Capital Ventures LLC1,652,605$19.04M5.2%N/A7.913% 2/10/2023NEA Management Company LLC481,677$4.44M0.2%N/A2.306% 2/1/2023Bank of Montreal Can42,444$545K0.0%N/A0.203% (Data available from 1/1/2016 forward)Remove Ads ACRV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ACRV shares? During the previous two years, 31 institutional investors and hedge funds held shares of Acrivon Therapeutics. The most heavily invested institutionals were Perceptive Advisors LLC ($31.09M), Citadel Advisors LLC ($12.76M), Sands Capital Ventures LLC ($12.31M), Vanguard Group Inc. ($3.63M), Marshall Wace LLP ($3.60M), Acorn Capital Advisors LLC ($2.44M), and Federated Hermes Inc. ($2.16M).Learn more on ACRV's institutional investors. What percentage of Acrivon Therapeutics stock is owned by institutional investors? 71.62% of Acrivon Therapeutics stock is owned by institutional investors. Learn more on ACRV's institutional investor holdings. Which institutional investors have been buying Acrivon Therapeutics stock? Of the 24 institutional investors that purchased Acrivon Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Perceptive Advisors LLC ($2.35M), Sands Capital Ventures LLC ($470K), Acorn Capital Advisors LLC ($405.24K), Marshall Wace LLP ($351.40K), Exome Asset Management LLC ($116.76K), Baker BROS. Advisors LP ($52.89K), and State Street Corp ($47.23K). How much institutional buying is happening at Acrivon Therapeutics? Institutional investors have bought a total of 4,026,349 shares in the last 24 months. This purchase volume represents approximately $23.99M in transactions. Which Acrivon Therapeutics major shareholders have been selling company stock? Of the 13 institutional investors that sold Acrivon Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Federated Hermes Inc. ($287.71K), Marshall Wace LLP ($212.07K), Renaissance Technologies LLC ($48.10K), Charles Schwab Investment Management Inc. ($30.12K), Exchange Traded Concepts LLC ($22.52K), Citadel Advisors LLC ($20.98K), and Trexquant Investment LP ($13.51K). How much institutional selling is happening at Acrivon Therapeutics? Institutional investors have sold a total of 668,828 shares in the last 24 months. This volume of shares sold represents approximately $5.76M in transactions. Related Companies Inhibrx Institutional Ownership ProKidney Institutional Ownership Prime Medicine Institutional Ownership Eledon Pharmaceuticals Institutional Ownership Voyager Therapeutics Institutional Ownership Amarin Institutional Ownership INmune Bio Institutional Ownership MediWound Institutional Ownership Inventiva Institutional Ownership Genfit Institutional Ownership This page (NASDAQ:ACRV) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACRV Stock Free ACRV Stock Alerts